Open an account

Minerva Surgical

UTRS · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About UTRS

Minerva Surgical, Inc. is a medical technology company. The company is headquartered in Santa Clara, California and currently employs 174 full-time employees. The company went IPO on 2021-10-22. The firm designs, manufactures, distributes, and commercializes a suite of products that offer effective alternatives to hysterectomy, with a focus on diagnosing and treating the underlying causes of Abnormal Uterine Bleeding (AUB). Its solutions are designed for use across a variety of care settings and focused on improving clinical outcomes and preserve uterine anatomy. The company delivers devices that treat the root causes of AUB in both the normal and irregular shaped uterus. The firm's products include Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Operative Hysteroscopy System (Symphion), Resectr Tissue Resection Device (Resectr), and HERizon Disposable Hysteroscope. Its Minerva EAS includes PlasmaSense Technology, which monitors uterine cavity. The company also provides HERizon Hysto-Kit, which supports in-office hysteroscopy.

Employees
174
Headquarters
Santa Clara, California
Listed
Oct 22, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
minervasurgical.com

UTRS key statistics

Market cap
888
Price-earnings ratio
0.00
Dividend yield
—
Average volume
35
Volume
51
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.001
52 Week low
$0.00

Minerva Surgical (UTRS) at a glance

As of Oct 19, 2026, Minerva Surgical (UTRS) shares are priced at $0.0001, giving the company a market cap of 888 and a price-to-earnings ratio of 0.00.

Volume so far is 51 shares, above the average of 35 shares a day.

Over the past year Minerva Surgical has ranged from $0.00 to $0.001, and now sits 10% of the way up that range.

Minerva Surgical met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY23 it reported -$0.81 per share against an estimate of -$1.02.

UTRS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 25.6% on average.

  1. Q4 FY21: reported -$5.20 per share against an estimate of -$5.97
  2. Q1 FY22: reported -$7.60 per share against an estimate of -$6.32
  3. Q2 FY22: reported -$4.00 per share against an estimate of -$6.94
  4. Q3 FY22: reported -$8.00 per share against an estimate of -$5.71
  5. Q4 FY22: reported -$4.00 per share against an estimate of -$4.28
  6. Q1 FY23: reported -$2.40 per share against an estimate of -$2.24
  7. Q2 FY23: reported -$1.00 per share against an estimate of -$1.84
  8. Q3 FY23: reported -$0.81 per share against an estimate of -$1.02

Similar companies

Companies in the same industry as Minerva Surgical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.